| For: | Stolfi C, Pellegrini R, Franzè E, Pallone F, Monteleone G. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol 2008; 14(28): 4434-4439 [PMID: 18680220 DOI: 10.3748/wjg.14.4434] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i28/4434.htm |
| Number | Citing Articles |
| 1 |
Joanna Słoka, Marcel Madej, Barbara Strzalka-Mrozik. Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer. Molecules 2023; 28(13) doi: 10.3390/molecules28135081
|
| 2 |
Jae Hee Cheon. Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists. Journal of Rheumatic Diseases 2021; 28(1) doi: 10.4078/jrd.2021.28.1.4
|
| 3 |
Fotios S. Fousekis, Konstantinos Mpakogiannis, Panagiotis Filis, Alexandros Skamnelos, Dimitrios K. Christodoulou, Davide Mauri, Konstantinos H. Katsanos. Exploring Chemoprevention in Colorectal Cancer for Patients with Inflammatory Bowel Disease: Mechanisms of Action and Clinical Aspects. Cancers 2025; 17(2) doi: 10.3390/cancers17020229
|
| 4 |
Venkataraman Subramanian, Richard F. Logan. Chemoprevention of colorectal cancer in inflammatory bowel disease. Best Practice & Research Clinical Gastroenterology 2011; 25(4-5) doi: 10.1016/j.bpg.2011.09.003
|
| 5 |
Maximilian Hoffmann, Theresa A. Kant, Ramona Emig, Johanna S. E. Rausch, Manja Newe, Mario Schubert, Karolina Künzel, Luise Winter, Erik Klapproth, Rémi Peyronnet, Ursula Ravens, Ali El-Armouche, Stephan R. Künzel. Repurposing mesalazine against cardiac fibrosis in vitro. Naunyn-Schmiedeberg's Archives of Pharmacology 2021; 394(3) doi: 10.1007/s00210-020-01998-9
|
| 6 |
Rishu Dheer, Julie M. Davies, Maria T. Abreu. Intestinal Tumorigenesis. 2015; doi: 10.1007/978-3-319-19986-3_8
|
| 7 |
Marcel Madej, Ilona Nowak, Barbara Strzałka-Mrozik, Magdalena Kimsa-Dudek, Celina Kruszniewska-Rajs, Joanna Magdalena Gola. Mesalazine Regulates DUSP1, DUSP4, and DUSP5 Expression in Colorectal Cancer: In Vitro and Bioinformatic Evidence. Pharmaceutics 2025; 18(1) doi: 10.3390/pharmaceutics18010029
|
| 8 |
Reena Khanna, John K. Marshall. Crohn's Disease and Ulcerative Colitis. 2017; doi: 10.1007/978-3-319-33703-6_38
|
| 9 |
Lily P.H. Yang, Paul L. McCormack. MMX® Mesalazine. Drugs 2011; 71(2) doi: 10.2165/11205870-000000000-00000
|
| 10 |
Yu Nishida, Shuhei Hosomi, Koji Fujimoto, Yumie Kobayashi, Rieko Nakata, Hirotsugu Maruyama, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuhiro Fujiwara. Impact of 5-Aminosalicylic Acid on Ustekinumab in Inflammatory Bowel Disease: A Retrospective Medical Claims Analysis. Inflammatory Bowel Diseases 2025; 31(9) doi: 10.1093/ibd/izaf001
|
| 11 |
Balakrishnan S. Ramakrishna, Govind K. Makharia, Philip Abraham, Uday C. Ghoshal, Venkataraman Jayanthi, Brij Kishore Agarwal, Vineet Ahuja, Deepak K. Bhasin, Shobna J. Bhatia, Gourdas Choudhuri, Sunil Dadhich, Devendra C. Desai, Gopal Krishna Dhali, Bhaba Dev Goswami, Sanjeev K. Issar, Ajay K. Jain, Rakesh Kochhar, Ajay Kumar, Goundappa Loganathan, Sri Prakash Misra, C. Ganesh Pai, Sujoy Pal, Anna Pulimood, Amarender S. Puri, Ganesh N. Ramesh, Gautam Ray, Shivaram P. Singh, Ajit Sood, Manu Tandan. Indian Society of Gastroenterology consensus on ulcerative colitis. Indian Journal of Gastroenterology 2012; 31(6) doi: 10.1007/s12664-012-0259-0
|
| 12 |
A. LYAKHOVICH, C. GASCHE. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Alimentary Pharmacology & Therapeutics 2010; 31(2) doi: 10.1111/j.1365-2036.2009.04195.x
|
| 13 |
Sung-hee Han, Jonghun Lee. Chemoprevention of Colorectal Cancer in Inflammatory Bowel Disease. The Korean Journal of Gastroenterology 2014; 63(1) doi: 10.4166/kjg.2014.63.1.3
|
| 14 |
Reena Khanna, John K. Marshall. Crohn's Disease and Ulcerative Colitis. 2012; doi: 10.1007/978-1-4614-0998-4_36
|
| 15 |
Nonna Ogurchenok, Konstantin Khalin, Igor Bryukhovetskiy. Chemoprophylaxis of precancerous lesions in patients who are at a high risk of developing colorectal cancer (Review). Medicine International 2024; 4(3) doi: 10.3892/mi.2024.149
|
| 16 |
Xi Yang, Fengyi Zhang, Yajing Wang, Min Cai, Qing Wang, Qinglong Guo, Zhiyu Li, Rong Hu. Oroxylin A Inhibits Colitis-associated Carcinogenesis Through Modulating the IL-6/STAT3 Signaling Pathway. Inflammatory Bowel Diseases 2013; doi: 10.1097/MIB.0b013e318293c5e0
|
| 17 |
Miwa Hirai, Yasuhiro Kanatani, Takashi Ueda, Masaya Sano, Hiroaki Arai, Yurin Miyake, Naoko Tomita, Shota Nemoto, Hidekazu Suzuki. Analysis of Risk Factors for Colorectal Cancer Associated with Ulcerative Colitis Using Machine Learning: A Retrospective Longitudinal Study Using a National Database in Japan. Cancers 2025; 17(23) doi: 10.3390/cancers17233752
|
| 18 |
I. KÜBLER, M. J. KOSLOWSKI, M. GERSEMANN, K. FELLERMANN, J. BEISNER, S. BECKER, K. ROTHFUSS, K. R. HERRLINGER, E. F. STANGE, J. WEHKAMP. Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn’s disease. Alimentary Pharmacology & Therapeutics 2009; 30(6) doi: 10.1111/j.1365-2036.2009.04070.x
|
| 19 |
Mohab Ragab, Heidi Schlichting, Maren Hicken, Patricia Mester, Misa Hirose, Larissa N. Almeida, Lea Christiansen, Saleh Ibrahim, Hauke Christian Tews, Senad Divanovic, Christian Sina, Stefanie Derer. Azathioprine promotes intestinal epithelial cell differentiation into Paneth cells and alleviates ileal Crohn’s disease severity. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-63730-4
|
| 20 |
Carmine Stolfi, Roberta Caruso, Eleonora Franzè, Angelamaria Rizzo, Angela Rotondi, Ivan Monteleone, Massimo Claudio Fantini, Francesco Pallone, Giovanni Monteleone. 2-Methoxy-5-Amino-N-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression. Molecular Cancer Therapeutics 2011; 10(10) doi: 10.1158/1535-7163.MCT-11-0316
|
| 21 |
S Danese, A Mantovani. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin–Yang interplay between inflammation and cancer. Oncogene 2010; 29(23) doi: 10.1038/onc.2010.109
|
| 22 |
Joanna Słoka, Barbara Strzałka-Mrozik, Sebastian Kubica, Ilona Nowak, Celina Kruszniewska-Rajs. Influence of Mesalazine on Ferroptosis-Related Gene Expression in In Vitro Colorectal Cancer Culture. Biomedicines 2025; 13(1) doi: 10.3390/biomedicines13010219
|
| 23 |
Ming-zhe Ma, Gang Chen, Peng Wang, Wen-hua Lu, Chao-feng Zhu, Ming Song, Jing Yang, Shijun Wen, Rui-hua Xu, Yumin Hu, Peng Huang. Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. Cancer Letters 2015; 368(1) doi: 10.1016/j.canlet.2015.07.031
|
| 24 |
S. PARENTI, F. FERRARINI, R. ZINI, M. MONTANARI, L. LOSI, B. CANOVI, S. FERRARI, A. GRANDE. Mesalazine inhibits the β‐catenin signalling pathway acting through the upregulation of μ‐protocadherin gene in colo‐rectal cancer cells. Alimentary Pharmacology & Therapeutics 2010; 31(1) doi: 10.1111/j.1365-2036.2009.04149.x
|
| 25 |
Shafina Siddiqui, Ankita Jaywant Deshmukh, Priyanka Mudaliar, Apoorva Jagannath Nalawade, Deepak Iyer, Jyotirmoi Aich. Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline—a review. Journal of the Egyptian National Cancer Institute 2022; 34(1) doi: 10.1186/s43046-022-00137-0
|
| 26 |
Cristiana Perrotta, Paolo Pellegrino, Eliana Moroni, Clara De Palma, Davide Cervia, Piergiorgio Danelli, Emilio Clementi. Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug. Gastroenterology Research and Practice 2015; 2015 doi: 10.1155/2015/456895
|
| 27 |
Shun-Wen Hsiao, Hsu-Heng Yen, Yang-Yuan Chen. Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease. Gut and Liver 2022; 16(6) doi: 10.5009/gnl210479
|
| 28 |
|
| 29 |
Song I Bae, You Sun Kim. Colon Cancer Screening and Surveillance in Inflammatory Bowel Disease. Clinical Endoscopy 2014; 47(6) doi: 10.5946/ce.2014.47.6.509
|
| 30 |
Hyun-Young Kim, Se-Lim Kim, Young-Ran Park, Yu-Chuan Liu, Seung Young Seo, Seong Hun Kim, In Hee Kim, Seung Ok Lee, Soo Teik Lee, Sang Wook Kim. Balsalazide Potentiates Parthenolide-Mediated Inhibition of Nuclear Factor-κB Signaling in HCT116 Human Colorectal Cancer Cells. Intestinal Research 2015; 13(3) doi: 10.5217/ir.2015.13.3.233
|
| 31 |
Maximilian J. Waldner, Stefan Wirtz, André Jefremow, Moritz Warntjen, Clemens Neufert, Raja Atreya, Christoph Becker, Benno Weigmann, Michael Vieth, Stefan Rose-John, Markus F. Neurath. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. Journal of Experimental Medicine 2010; 207(13) doi: 10.1084/jem.20100438
|
| 32 |
Marios Efthymiou, Andrew C.F. Taylor, Michael A. Kamm. Cancer surveillance strategies in ulcerative colitis. Inflammatory Bowel Diseases 2011; 17(8) doi: 10.1002/ibd.21540
|
| 33 |
Hans Herfarth, Stephan R. Vavricka. 5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?. Inflammatory Intestinal Diseases 2022; 7(1) doi: 10.1159/000518865
|
| 34 |
Tong Wang, Yaojing Huang, Peng Jiang, Xin Yuan, Qian Long, Xiaochen Yan, Yuwei Huang, Zongkui Wang, Changqing Li. Research progress on anti-inflammatory drugs for preventing colitis-associated colorectal cancer. International Immunopharmacology 2025; 144 doi: 10.1016/j.intimp.2024.113583
|
| 35 |
Darla R. Shores, David G. Binion, Bruce A. Freeman, Paul R.S. Baker. New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease. Inflammatory Bowel Diseases 2011; 17(10) doi: 10.1002/ibd.21560
|